Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Christine Gebski net worth and biography

Christine Gebski Biography and Net Worth

Insider of Repligen

Christine Gebski joined Repligen in May 2015 as Senior Vice President, Filtration and Chromatography where she oversees the general management and strategy of the companies’ upstream and downstream filtration and chromatography portfolio. Ms. Gebski also manages the Customer Service and Field Applications functions within the company, ensuring strong customer experience. Prior to joining Repligen, Ms. Gebski was Head of the Chromatography Business Unit within the Bioproduction Division of Thermo Fisher Scientific. At Thermo Fisher she managed the Global Process Chromatography Applications and R&D functions for ten years. Before joining Thermo Fisher Scientific, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry having held positions of increasing responsibility at Genzyme, TKT/Shire and EMD Pharmaceuticals. She has significant experience in downstream process development and engineering, technology transfer and validation across a variety of biological molecule classes and diagnostic reagents. She holds a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.

What is Christine Gebski's net worth?: The estimated net worth of Christine Gebski is at least $4.00 million as of November 10th, 2023. Ms. Gebski owns 28,787 shares of Repligen stock worth more than $3,998,514 as of November 21st. This net worth evaluation does not reflect any other investments that Ms. Gebski may own. Learn More about Christine Gebski's net worth.
How do I contact Christine Gebski?: The corporate mailing address for Ms. Gebski and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at [email protected]. Learn More on Christine Gebski's contact information.
Has Christine Gebski been buying or selling shares of Repligen?: Christine Gebski has not been actively trading shares of Repligen during the past quarter. Most recently, Christine Gebski sold 3,788 shares of the business's stock in a transaction on Friday, November 10th. The shares were sold at an average price of $147.13, for a transaction totalling $557,328.44. Following the completion of the sale, the insider now directly owns 28,787 shares of the company's stock, valued at $4,235,431.31. Learn More on Christine Gebski's trading history.
Who are Repligen's active insiders?: Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (Executive Chair), Ralf Kuriyel (VP), Martin Madaus (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.
Are insiders buying or selling shares of Repligen?: In the last year, Repligen insiders bought shares 2 times. They purchased a total of 3,615 shares worth more than $449,938.10. In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 72,325 shares worth more than $12,382,469.27. The most recent insider tranaction occured on September, 10th when Director Anthony Hunt sold 22,191 shares worth more than $3,225,905.67. Insiders at Repligen own 1.2% of the company. Learn More about insider trades at Repligen.
Information on this page was last updated on 9/10/2024.

Christine Gebski Insider Trading History at Repligen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/10/2023	Sell	3,788	$147.13	$557,328.44	28,787
8/4/2022	Sell	3,357	$243.01	$815,784.57	30,735
5/14/2021	Sell	445	$172.25	$76,651.25	36,695
3/16/2021	Sell	1,400	$196.88	$275,632.00	37,140

Christine Gebski Buying and Selling Activity at Repligen

Repligen Company Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $138.90

$128.91

$139.17

50 Day Range

MA: $140.30

$123.41

$150.47

2 Week Range

Now: $138.90

$113.50

$211.13

Volume

898,461 shs

Average Volume

680,106 shs

Market Capitalization

$7.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Get Your Free Gold Guide